Picture of IDEXX Laboratories logo

IDXX — IDEXX Laboratories News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareBalancedLarge CapHigh Flyer

IDEXX Q1 revenue rises 14%, beats analyst estimates

Overview

Pet diagnostics firm's Q1 revenue rose 14%, beating analyst expectations

Q1 EPS increased 17% to $3.47, driven by strong commercial performance

Company raised 2026 revenue and EPS outlook on strong CAG Diagnostics demand

Outlook

IDEXX raises 2026 revenue guidance to $4.68 bln-$4.76 bln, up $42 mln at midpoint

Company lifts 2026 EPS outlook to $14.45-$14.90, up $0.13 at midpoint

IDEXX now sees 2026 organic revenue growth of 7.7%-9.7%, up from 7.0%-9.0%

Result Drivers

CAG DIAGNOSTICS GROWTH - Double-digit recurring revenue gains in Companion Animal Group, supported by strong commercial execution, volume growth, and innovation

INTERNATIONAL AND U.S. CONTRIBUTIONS - International regions saw 21% reported and 12% organic CAG Diagnostics recurring revenue growth; U.S. growth aided by easing clinical visit pressures and increased diagnostic frequency

Company press release: ID:nBw18HPk8a

Key Details

MetricBeat/MissActualConsensus Estimate
Q1 RevenueBeat$1.14 bln$1.11 bln (12 Analysts)
Q1 EPS$3.47
Q1 Gross Margin63.40%
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com. (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on IDEXX Laboratories

See all news